Drug Profile
Cibinetide - Araim Pharmaceuticals
Alternative Names: ARA 290Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Araim Pharmaceuticals
- Developer Araim Pharmaceuticals; Karolinska Institute; National Institute on Aging; Queens University Belfast
- Class Analgesics; Anti-inflammatories; Antidepressants; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Hepatoprotectants; Peptides; Radioprotectives
- Mechanism of Action Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cardiovascular disorders; Diabetic macular oedema; Diabetic neuropathies; Neuropathic pain; Rheumatoid arthritis
- No development reported Diabetic nephropathies; Inflammatory bowel diseases; Non-alcoholic steatohepatitis; Radiation injuries; Retinal disorders; Systemic lupus erythematosus; Transplant rejection; Wounds
- Discontinued Depressive disorders; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 28 Jun 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA
- 28 Jun 2022 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in USA